Status:
COMPLETED
Effect of Antacids on the Pharmacokinetics of Raltegravir
Lead Sponsor:
University of Colorado, Denver
Conditions:
HIV Infections
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.
Detailed Description
This study will determine if an interaction occurs between the HIV medicine raltegravir and an antacid. A prior study found an interaction with another medicine like raltegravir called elvitegravir an...
Eligibility Criteria
Inclusion
- Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days prior to study entry.
- Age greater than or equal to 18 but less than or equal to 60 years.
- Ability and willingness to give written informed consent.
- Within 30% (+/-) of ideal body weight and total body weight of ≥ 50 kg.
- Hematology, Metabolic Profile, Renal, and Hepatic Function tests all within normal limits.
- Creatine kinase (CK) less than 3 times the upper limit of normal
Exclusion
- Pregnancy or breast-feeding.
- Women and men of reproductive potential who are actively engaging in sexual activity or assisted reproductive technology with the intent of pregnancy.
- Allergy/sensitivity to raltegravir.
- Allergy/sensitivity to antacids.
- Active drug or alcohol abuse or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. While on study, subjects will be instructed not to consume alcohol for 48 hours prior the screening visit, and for the 24 hours preceding the intensive pharmacokinetic (PK) study visits and for 24 hours following the completion of the study visits.
- Any medical condition that, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol.
- Participation in any investigational drug studies within 30 days prior to study entry.
- History of or active cardiovascular, renal, hematologic, hepatic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that might interfere with drug absorption.
- Use of investigational, prescription, and over-the-counter medications within 14 days of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and oral contraceptives
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00944307
Start Date
July 1 2009
End Date
December 1 2009
Last Update
June 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045